Cancer Drug Responses Camp Lejeune NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Alfred Jackson Newman
(704) 841-8151
3036 Senna Drive
Matthews, NC
Specialty
Hematology / Oncology

Data Provided by:
William Mc Nulty, MD
(910) 763-5182
1515 Doctors Cir
Wilmington, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Sc Sch Of Med, Columbia Sc 29208
Graduation Year: 1982

Data Provided by:
Timothy Earl Cloninger, MD
(704) 333-7376
200 Queens Rd
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1966
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology; Sou

Data Provided by:
John Hugh Bryan, MD
(910) 609-6690
PO Box 41208
Fayetteville, NC
Specialties
Oncology (Cancer), Radiation Oncology, Pediatrics
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1969
Hospital
Hospital: Cape Fear Valley Med Center, Fayetteville, Nc; Southeastern Reg Med Ctr, Lumberton, Nc
Group Practice: South East Radiation Oncology

Data Provided by:
Jennie Robertson Crews, MD
(252) 975-4308
628 E 12th St
Washington, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1990
Hospital
Hospital: Beaufort County Hosp, Washington, Nc
Group Practice: Ecu Physicians Brody School Of Medicine

Data Provided by:
Orren Beaty III, DO
(828) 213-1740
50 Doctors Dr Ste 105
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Kirksville Coll Of Osteo Med, Kirksville Mo 63501
Graduation Year: 1988

Data Provided by:
Cassandra Nicole Moore, MD
(919) 684-5199
DUME 3841,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Nm Sch Of Med, Albuquerque Nm 87131
Graduation Year: 1999

Data Provided by:
Richard Alan Brodkin, MD
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1974
Hospital
Hospital: Forsyth Mem Hosp, Winston Salem, Nc
Group Practice: Piedmont Hematology Oncology Associates

Data Provided by:
Mariealane Hellner
(704) 770-3400
4501 Cameron Valley Pkwy
Charlotte, NC
Specialty
Hematology / Oncology

Data Provided by:
Mark Yoffe, MD
(919) 781-7070
4420 Lake Boone Trl
Raleigh, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Fl Coll Of Med, Gainesville Fl 32610
Graduation Year: 1977

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com